6. Cai, H.#, Zhang, Z.#, Wang, M.#, Zhong, B.#, Li, Q., Zhong, Y., Wu, Y.*, Ying, T.*, Tang, J.* Pretrainable geometric graph neural network for antibody affinity maturation. Nat Commun. 15(1):7785, 2024

7. Wang, M., Ying, T.*, Wu, Y.* Single-domain antibodies as therapeutics for solid tumor treatment. Acta Pharm Sin B., 14(7):2854-2868, 2024

8. Wang, X,. Kang, H., Huang, K., Guo, M., Wu, Y.*, Ying, T., Liu, Y., Wei, D.* Antibody Nanotweezer Constructing Bivalent Transistor-Biomolecule Interface with Spatial Tolerance. Nano Lett. 24(13):3914-3921, 2024

9. Chen, Y.#, Li, Y.#, Zhou, Q.#, Cong, Z., Lin, S., Yan, J., Chen, X., Yang, D.*, Ying, T.*, Wang, M.W.*. A homotrimeric GPCR architecture of the human cytomegalovirus revealed by cryo-EM. Cell Discov. 16;10(1):52, 2024.

10. Liang, M.#*, Wang, L.#, Tian, X.#, Wang, K.#, Zhu, X.#, Huang, L., Li, Q., Ye, W., Chen, C., Yang, H., Wu, W., Chen, X., Zhu, X., Xue, Y., Wan, W., Wu, Y., Lu, L., Wang, J., Zou, H., Ying, T.*, Zhou, F.*. Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Ann Rheum Dis. 83(9):1144-1155, 2024

11. Zhu, X.Y.#, Li, Q.X.#, Kong, Y., Huang, K.K., Wang, G., Wang, Y.J., Lu, J., Hua, G.Q., Wu, Y.*, Ying, T.* A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin, 45(3):609-618, 2024

12. Sun, W., Wu, Y.*, Ying, T.* Progress in novel delivery technologies to improve efficacy of therapeutic antibodies. Antiviral Res, 225:105867, 2024

13. Ye, F., Li, C., Liu, FL., Liu, X., Xu, P., Luo, RH., Song, W., Zheng YT.*, Ying, T.*, Yu, B., Wang, P.*. Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function. Natl Sci Rev, 11(2):nwae030, 2024

14. Hao, A.#, Song, W.#, Li, C.#, Zhang, X., Tu, C., Wang, X., Wang, P., Wu, Y.*, Ying, T.*, Sun, L.* Defining a highly conserved cryptic epitope for antibody recognition of SARS-CoV-2 variants. Signal Transduct Target Ther, 8(1), 269, 2023

15. Li, Q., Lu, J., Li, J., Zhang, B., Wu, Y.*, Ying, T.* Antibody-based cancer immunotherapy by targeting regulatory T cells. Front Oncol, 13, 1157345, 2023

16. Li, T.#, Li, Y.#, Zhu, X.#, He, Y., Wu, Y., Ying, T.*, Xie, Z.* Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction. Semin Cancer Biol, 91, 50-69, 2023

17. Li, C., Yang, Z.*, Wu, Y.*, Ying, T.* Evaluation of vaccine effectiveness against SARS-CoV-2 variants by serological epitope profiling. Clin Transl Med, 13(1), e1182, 2023

18. Wu, H., Hu, D., Li Q., Wang, C., Zhu, X., Li, W., Chen, B., Ji, P., Huang, K., Huang, J., Dimitrov, D.S., Wu, Y.*, Ying, T.* Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy. Engineering, 21: 203-213., 2023

19. Li, C.#, Zhan, W.#, Yang, Z.#, Tu, C.#, Hu, G.#, Zhang, X., Song, W., Du, S., Zhu, Y., Huang, K., Kong, Y., Zhang, M., Mao, Q., Gu, X., Zhang, Y., Xie, Y., Deng, Q., Song, Y., Chen, Z., Lu, L., Jiang, S., Wu, Y.*, Sun, L.*, Ying, T.* Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 185(8):1389-1401.e18, 2022

20. Li, C., Ying, T.*, Dimitrov, D.S.*, Wu, Y.* Counter changes with changelessness: cope with SARS-CoV-2 immune evasion by targeting cryptic epitopes. Life Medicine, 1(1):24-6, 2022

21. Tian, X.#, Zhu, X.#, Song, W., Yang, Z., Wu, Y.*, Ying, T.* The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2. Emerg Microbes Infect, 11(1):1186-1190, 2022

22. Wang, C.#, Hong, J.#*, Yang, Z.#, Zhou, X., Yang, Y., Kong, Y., Chen, B., Wu, H., Qian, B.Z., Dimitrov, D.S., Zhou, X., Wu, Y.*, Ying, T.* Design of a Novel Fab‐Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 6(2):e2100966, 2022

23. Shi, Y., Wu, H., Hu, W., Jin, Y., Kong, M., Wang, Y., Chen, B., Li, Q., Huang, K., Yang, Z., Li, F.*, Wu, Y.*, Ying, T.* An antigen-strengthened dye-modified fully-human-nanobody-based immunoprobe for second near infrared bioimaging of metastatic tumors. Biomaterials, 287:121637, 2022

24. Wu, Y.#*, Li, Q.#, Kong, Y.#, Wang, Z.#, Lei, C.#, Li, J., Ding, L., Wang, C., Cheng, Y., Wei, Y., Song, Y., Yang, Z., Tu, C., Ding, Y.*, Ying, T.* A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther, 30(8):2785-2799, 2022

25. Shi, Y., Tang, M., Zhang, S., Hu, C., Li, C., Li Q., Huang, K., Song, W., Li, Z., Li, W., Yang, Z., Wu, Y., Li, F.*, Hu, J.*, Ying, T.* First Nerve-Related Immunoprobe for Guidance of Renal Denervation through Colocalization of NIR-II and Photoacoustic Bioimaging. Adv Healthc Mater, e2201212, 2022

26. Chen, B.#, Chen, Y.#, Li, J.#, Wang C., Song, W., Wen, Y., Lin, J.*, Wu, Y.*, Ying, T.* A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. mBio, e0161222, 2022

27. Tian, X.#, Hong, B.#, Zhu, X.#, Kong, D., Wen, Y., Wu, Y., Ma, L., Ying, T.* Characterization of human IgM and IgG repertoires in individuals with chronic HIV-1 infection. Virol Sin, S1995-820X(22)00042-6, 2022

28. Zhan, W.#, Tian, X.#, Zhang, X.#, Xing, H.#, Song, W., Liu, Q., Hao, A., Hu, Y., Zhang, M., Ying, T.*, Chen, Z.*, Lan, F.*, Sun, L.* Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. J Virol, 96(16):e0048022, 2022

29. Huang, K., Ying, T.*, Wu, Y.* Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses, 14(6):1162, 2022

30. Yang, Z.*, Li, C., Song, Y., Ying, T.*, Wu, Y.* Inhalable antibodies for the treatment of COVID-19. Innovation (Camb), 3(6):100328, 2022

31. Yang, Z.#*, Wang, Y.#, Jin, Y.#, Zhu, Y.#, Wu, Y.#, Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., Huang, A., Zhou, S., Xia, S., Tian, X., Peng, C., Chen, C., Shi, Y., Hu, G., Du, S., Wang, Y., Xie, Y., Jiang, S., Lu, L., Sun, L., Song, Y.*, Ying, T.* A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Target Ther, 6(1), 378, 2021

32. Li, C.#, Tian, X.#, Jia, X.#, Wan, J., Lu, L., Jiang, S., Lan, F., Lu, Y.*, Wu, Y.*, Ying, T.* The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther, 6(1), 132, 2021

33. Chen, G., Kong, Y., Li, Y., Huang, A., Wang, C., Zhou, S., Yang, Z., Wu, Y.*, Ren, J.*, Ying, T.* A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. Biomolecules, 11(10), 2021

34. Zhang, Z.#, Chu, Y.#, Li, C.#, Tang, W., Qian, J., Wei, X., Lu, W., Ying, T.*, Zhan, C.* Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. J Control Release, 330, 493-501, 2021

35. Jin, Y. J., Yu, D., Tian, X. L., Li, H. X., Zhou, X. C., Kong, Y., Zhang, W., Zhang, L., Lei, C., Yang, Z. L., Tu, C., Wu, Y.*, Ying, T.* A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms. Acta Pharmacol Sin, 2021

36. Hong, B.*, Wang, L., Huang, C., Hong, X., Liu, A., Li, Q., Liu, Q., Su, L., Wang, L., Wang, C., Ying, T.* Decrease of Clone Diversity in IgM Repertoires of HBV Chronically Infected Individuals With High Level of Viral Replication. Front Microbiol, 11, 615669, 2021

37. Tian, X.#, Li, C.#, Wu, Y.*, Ying, T.* Insights into biological therapeutic strategies for COVID-19. Fundamental Research, 1(2), 166-178, 2021

38. Zhu, X., Yu, F.*, Wu, Y.*, Ying, T.* Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther, 4(2), 89-98, 2021

39. Tang, W., Zhang, Z., Li, C., Chu, Y., Qian, J., Ying, T.*, Lu, W.*, Zhan, C.*, Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv. Nano Lett, 21(23):10107-10113, 2021

40. Tian, X.#, Li, C.#, Wu, Y.*, Ying T.* Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications. Small Methods, 4(10), 2020

41. Wu, Y.*, Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., Yang, Z., Lu, L., Jiang, S., Ying, T.* Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe, 27(6), 891-898.e895, 2020

42. Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., Wu, Y., Ying, T., Liu, S., Shi, Z., Jiang, S., Lu, L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol, 17(7), 765-767, 2020

43. Yu, F., Xiang, R., Deng, X., Wang, L., Yu, Z., Tian, S., Liang, R., Li, Y., Ying, T.*, Jiang, S.* Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther, 5(1), 212, 2020

44. Deng, X.#, Tian, S.#, Yu, Z.#, Wang, L., Liang, R., Li, Y., Xiang, R., Jiang, S.*, Ying, T.*, Yu, F.* Development of small-molecule inhibitors against hantaviruses. Microbes Infect, 22(6-7), 272-277, 2020

45. Li, Y., Lai, D. Y., Zhang, H. N., Jiang, H. W., Tian, X., Ma, M. L., Qi, H., Meng, Q. F., Guo, S. J., Wu, Y., Wang, W., Yang, X., Shi, D. W., Dai, J. B., Ying, T.*, Zhou, J.*, Tao, S. C.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol, 17(10), 1095-1097, 2020

46. Li, Y.#*, Wu, H.#, Chen, G., Wei, X., Wang, C., Zhou, S., Huang, A., Zhang, Z., Zhan, C., Wu, Y., Ying, T.* Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models. Front Oncol, 10, 1117, 2020

47. Tian, X.#, Li, C.#, Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z.*, Wu, Y.*, Ying, T.* Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 9(1), 382-385, 2020

48. Wang, Y., Hu, D., Wu, Y.*, Ying, T.* Recent advances in "universal" influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head. Front Med, 14(2), 149-159, 2020

49. Shi, B., Wu, Y., Wang, C., Li, X., Yu, F., Wang, B., Yang, Z., Li, J., Liang, M., Wen, Y.*, Ying, T.*, Yuan, Z.* Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine, 49, 247-257, 2019

50. Wang, L.#, Liang, R.#, Gao, Y.#, Li, Y., Deng, X., Xiang, R., Zhang, Y., Ying, T.*, Jiang, S.*, Yu, F.* Development of Small-Molecule Inhibitors Against Zika Virus Infection. Front Microbiol, 10, 2725, 2019

51. Wu, Y.#, Xue, J.#, Wang, C., Li, W., Wang, L., Chen, W., Prabakaran, P., Kong, D., Jin, Y., Hu, D., Wang, Y., Lei, C., Yu, D., Tu, C., Bardhi, A., Sidorov, I., Ma, L., Goldstein, H., Qin, C., Lu, L., Jiang, S., Dimitrov, D. S., Ying, T.* Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. J Virol, 93(20), 2019

52. Hong, B., Wen, Y., Ying, T.* Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications. Infect Disord Drug Targets, 19(3), 213-223, 2019

53. Hu, D.#, Zhu, Z.#, Li, S.#, Deng, Y.#, Wu, Y., Zhang, N., Puri, V., Wang, C., Zou, P., Lei, C., Tian, X., Wang, Y., Zhao, Q., Li, W., Prabakaran, P., Feng, Y., Cardosa, J., Qin, C., Zhou, X.*, Dimitrov, D. S.*, Ying, T.* A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathog, 15(6), e1007836, 2019

54. Liang, R., Wang, L., Zhang, N., Deng, X., Su, M., Su, Y., Hu, L., He, C., Ying, T.*, Jiang, S.*, Yu, F.* Development of Small-Molecule MERS-CoV Inhibitors. Viruses, 10(12), 2018

55. Hong, B., Wu, Y., Li, W., Wang, X., Wen, Y., Jiang, S., Dimitrov, D. S., Ying, T.* In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. Front Immunol, 9, 128, 2018

56. Lei, C., Gong, R., Ying, T.* Editorial: Antibody Fc Engineering: Towards Better Therapeutics. Front Immunol, 9, 2450, 2018

57. Jin, Y., Lei, C., Hu, D., Dimitrov, D. S., Ying, T.* Human monoclonal antibodies as candidate therapeutics against emerging viruses. Front Med, 11(4), 462-470, 2017

58. Bardhi, A., Wu, Y., Chen, W., Li, W., Zhu, Z., Zheng, J. H., Wong, H., Jeng, E., Jones, J., Ochsenbauer, C., Kappes, J. C., Dimitrov, D. S., Ying, T., Goldstein, H. Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. J Virol, 91(20), 2017

59. Yu, F.#, Song, H.#, Wu, Y.#, Chang, S. Y., Wang, L., Li, W., Hong, B., Xia, S., Wang, C., Khurana, S., Feng, Y., Wang, Y., Sun, Z., He, B., Hou, D., Manischewitz, J., King, L. R., Song, Y., Min, J. Y., Golding, H., Ji, X., Lu, L., Jiang, S., Dimitrov, D. S., Ying, T.* A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe, 22(4), 471-483.e475, 2017

60. Ying, T.*, Wen, Y., Dimitrov, D. S.* Precision immunomedicine. Emerg Microbes Infect, 6(4), e25, 2017

61. Wu, Y., Li, S., Du, L., Wang, C., Zou, P., Hong, B., Yuan, M., Ren, X., Tai, W., Kong, Y., Zhou, C., Lu, L., Zhou, X.*, Jiang, S.*, Ying, T.* Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect, 6(10), e89, 2017

62. Wu, Y., Jiang, S., Ying, T.* Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Front Immunol, 8, 1802, 2017

63. Wang, C., Wu, Y., Wang, L., Hong, B., Jin, Y., Hu, D., Chen, G., Kong, Y., Huang, A., Hua, G., Ying, T.* Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding. Front Immunol, 8, 1545, 2017

64. van Doremalen, N.#, Falzarano, D.#, Ying, T.#, de Wit, E., Bushmaker, T., Feldmann, F., Okumura, A., Wang, Y., Scott, D. P., Hanley, P. W., Feldmann, H., Dimitrov, D. S., Munster, V. J.* Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res, 143, 30-37, 2017

65. Ouyang, Y., Yin, Q., Li, W., Li, Z., Kong, D., Wu, Y., Hong, K., Xing, H., Shao, Y., Jiang, S.*, Ying, T.*, Ma, L.* Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Sci Rep, 7(1), 6222, 2017

66. Ying, T., Prabakaran, P., and Dimitrov, D.S.*, A systems approach to HIV-1 vaccines. Nat. Biotechnol. 8;34(1):44-6, 2016

67. Wu, Y., Jiang, S., Ying, T.*, From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. Expert. Opin. Biol. Ther. 16(12):1469-1478, 2016

68. Ying, T.*, Li, W., and Dimitrov, D.S., Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. J. Infect. Dis. 213(6):877-9, 2016

69. Wang, L., and Ying, T.*, New directions for half-life extension of protein therapeutics: the rise of antibody Fc domains and fragments. Curr. Pharm. Biotechno. 2016, 17(15):1348-1352

70. Ying, T.*, Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y., Wang, L., Li, W., Jiang, S., Dimitrov, D.S., and Zhou, T.*, Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6:8223, 2015

71. Ying, T.*, Wang, Y., Feng, Y., Prabakaran, P., Gong, R., Wang L., Crowder, K., and Dimitrov, D.S., Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. mAbs. 7(5):922-30, 2015

72. Ying, T.*, Li, H., Lu, L., Dimitrov, D.S., and Jiang, S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes. Infect. 17(2):142-8, 2015

73. Ying, T.*, Du, L., Ju, T.W., Prabakaran, P., Lau, C.C., Lu, L., Liu, Q., Wang, L., Feng, Y., Wang, Y., Zheng, B.J., Yuen, K.Y., Jiang, S., and Dimitrov, D.S.*, Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88(14):7796-805, 2014

74. Ying, T.*, Feng, Y., Wang, Y., Chen, W., and Dimitrov, D.S., Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. mAbs. 6:5, 1-10, 2014

75. Ying, T.*, Ju, T., Wang, Y., Prabakaran, P., and Dimitrov, D.S., Interactions of IgG1 CH2 and CH3 domains with FcRn, Front. Immunol. 5:146. doi: 10.3389, 2014

76. Ying, T.*, Gong, R., Ju, T.W., Prabakaran, P., and Dimitrov, D.S., Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim. Biophys. Acta. 1844(11):1977-1982, 2014

77. Ying, T.*, Chen, W., Feng, Y., Wang, Y., Gong, R., and Dimitrov, D.S., Engineered soluble monomeric IgG1 CH3- generation, mechanisms of function and implications for design of biological therapeutics. J. Biol. Chem. 288(35):25154-64, 2013

78. Ying, T.*, Chen, W., Gong, R., Feng, Y., and Dimitrov, D.S., Soluble monomeric IgG1 Fc. J. Biol. Chem. 287(23):19399-408, 2012